COMMENT FROM THE EDITOR-IN-CHIEF {#rry108s1}
================================

The Board of Editors of the *Journal of Radiation Research* is pleased to announce that Dr Hiroshi Harada is the winner of the 2018 Terasima Award, given for his outstanding paper published in the *Journal of Radiation Research* in 2016. In 2001, the *Journal of Radiation Research* established the Terasima Award honoring Dr Toyozo Terasima, a pioneer in Japan in the field of radiation research, and it has been presented to the authors of the most prominent paper each year since. In 2018, five papers were nominated for the Award, and the paper concerning hypoxia-inducible factor 1 (HIF-1) by Dr H. Harada \[[@rry108C1]\] received the highest evaluation. He received a certificate, a 100 000 yen award, and exemption from processing charges on his next article published in the *Journal of Radiation Research*.
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COMMENT FROM THE AUTHOR {#rry108s2}
=======================

It is my great honor to have received the prestigious *Journal of Radiation Research* Terasima Award for my paper entitled 'Hypoxia-inducible factor 1--mediated characteristic features of cancer cells for tumor radioresistance'. Tumor hypoxia has been attracting increasing attention in the fields of radiation biology and oncology since Thomlinson and Gray reported the existence of hypoxic cells in malignant solid tumors and suggested that they exert a negative impact on the outcome of radiation therapy. This unfavorable influence has been, at least partly, attributed to cancer cells acquiring a radioresistant phenotype through activation of the transcription factor, hypoxia-inducible factor 1 (HIF-1). Accumulating evidence, on the other hand, has recently revealed that, even though HIF-1 is recognized as an important regulator of cellular adaptive responses to hypoxia, it may not become active and induce tumor radioresistance under hypoxic conditions only. In the award-winning paper, I summarized the mechanisms by which HIF-1 is activated in cancer cells, not only under hypoxic conditions but also under normoxic conditions, through cancer-specific genetic alterations and the resultant imbalance in intermediate metabolites. In addition, I reviewed the most recent findings about the relevance of the HIF-1--mediated characteristic features of cancer cells, such as the production of antioxidants through reprogramming of the glucose metabolic pathway and cell cycle regulation, to tumor radioresistance.

Finally, I would like to express my sincere appreciation to my great mentor Prof. Masahiro Hiraoka (a professor emeritus of Kyoto University, Japan), my colleagues, and my family. I hope my students can publish their papers in *Journal of Radiation Research* and receive the Terasima award someday.
